PrecisemAb Biotech is a clinical needs–driven drug development company focused on overcoming safety challenges in antibody therapeutics, particularly on-target toxicity caused by antigen expression in normal tissues. By integrating clinical tumor specimen analysis, computational modeling, and protein engineering, PrecisemAb developed the patented Antibody Lock™ platform, which enables tumor microenvironment–specific activation of antibodies. This approach reduces systemic toxicity, minimizes side effects, and expands the therapeutic window.

The platform is protected by patents in 18 countries and was non-exclusively licensed to GlycoNex (Taiwan) in 2024, generating revenue and validating its commercial potential.

In parallel, PrecisemAb is advancing its proprietary antibody PSM101, with IND submissions planned in the United States and Taiwan in Q4 2027. The company is also expanding the Antibody Lock platform into next-generation modalities, including bispecific antibodies and antibody–drug conjugates (ADCs).

PrecisemAb has developed the patented Antibody Lock™ platform, a conditional activation technology designed to address one of the major limitations of antibody therapeutics: on-target toxicity in normal tissues. The platform incorporates a hinge-linked, protease-cleavable masking structure that temporarily blocks antibody binding activity in healthy tissues.

In disease microenvironments such as tumors, where protease activity is elevated, the masking structure is selectively cleaved, restoring the antibody’s binding ability and therapeutic function. This mechanism enables disease-site–specific activation, reducing systemic toxicity while preserving the intrinsic affinity, pharmacokinetics, and effector functions of the original antibody.

The Antibody Lock platform requires minimal structural modification and is broadly compatible with conventional antibodies as well as next-generation modalities, including bispecific antibodies and antibody–drug conjugates (ADCs). By improving selectivity and safety, the technology expands the therapeutic window and enables the development of targets previously limited by safety concerns.

1. Secure a U.S. collaboration/option-to-license and complete the next financing round to fund IND-enabling activities for our lead program (CMC, GLP tox, regulatory readiness). 

2. Build U.S. BD and investor pipeline through SelectUSA, and major biotech partnering events; advance at least one U.S. partner evaluation under NDA using our approximately three month lock-design package. In parallel, we plan to engage with biotech incubator/accelerator and specific ecosystem rationale to expand networking.